The cost efficiency of HPV vaccines is significantly underestimated due to omission of conization-associated prematurity with neonatal mortality and morbidity

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 2, 2012, Pages 243-251

  Soerge, Philipp ^a   Makowski, Lars ^a   Schippert, Cordula ^a   Staboulidou, Ismini ^a   Hille, Ursula ^a   Hillemanns, Peter ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Conisation; HPV; HPV vaccine; Neonatal morbidity; Neonatal mortality

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ANALYTICAL PARAMETERS; ARTICLE; CANCER SCREENING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE ASSOCIATION; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; LIFE YEARS SAVED; NEWBORN; NEWBORN DEATH; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONBIOLOGICAL MODEL; PAPILLOMAVIRUS INFECTION; PREMATURE LABOR; PREMATURITY; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VACCINATION; VACCINATION COVERAGE; VIRTUAL REALITY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CONIZATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; MASS VACCINATION; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; UTERINE CERVICAL NEOPLASMS;

EID: 84861804793     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.18519     Document Type: Article

References (50)

1. Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:1-3; PMID: 10451480; http://dx.doi.org/10.1002/(SICI)1096-9896 (199909)189:1〈12: :AID-PATH431〉3.0.CO;2-F
2. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al & HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
3. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102:325-39; PMID:20139221; http://dx.doi.org/10.1093/jnci/djp534
4. Pathirana D, Hillemanns P, Petry KU, Becker N, Brockmeyer NH, Erdmann R, et al. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 2009; 27:4551-9; PMID:19524337; http://dx.doi.org/10.1016/j.vaccine.2009.03.086
5. Martin-Hirsch P, Paraskevaidis E, Bryant A, Dickinson H, Keep S. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010; 16: CD001318.
6. Hillemanns P, Kimmig R, Dannecker C, Noorzai T, Diebold J, Thaler CJ, et al. [LEEP versus cold knife conization for treatment of cervical intraepithelial neoplasias]. Zentralbl Gynakol 2000; 122:35-42; PMID: 10785949
7. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and metaanalysis. Lancet 2006; 367:489-98; PMID:16473126; http://dx.doi.org/10.1016/ S0140-6736(06)68181-6
8. Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG 2010; 117:258-67; PMID:19943823; http://dx.doi.org/ 10.1111/j.1471-0528.2009.02438.x
9. van de Vijver A, Poppe W, Verguts J, Arbyn M. Pregnancy outcome after cervical conisation: a retrospective cohort study in the Leuven University Hospital. BJOG 2010; 117:268-73; PMID:19943824; http://dx.doi.org/10.1111/j. 1471-0528.2009.02437.x
10. Quenby S. Obstetric management of women after treatment for CIN. BJOG 2010; 117:243-4; PMID: 20078585; http://dx.doi.org/10.1111/j.1471-0528.2009. 02460.x
11. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004; 291:2100-6; PMID:15126438; http://dx.doi.org/10.1001/jama.291.17.2100
12. Soergel P, Makowski E, Makowski L, Schippert C, Hillemanns P. [What are the costs of conisation if considering pregnancy-associated complications?]. Geburtshilfe Frauenheilkd 2011; 71:199-204; http://dx.doi.org/10.1055/s-0030- 1270941
13. Ferko N, Postma M, Gallivan S, Kruzikas D, Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 2008; 26(Suppl 5): F3-15; PMID:18992381; http://dx.doi.org/10.1016/j.vaccine.2008.02.004
14. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 2010; 16:217-30; PMID:20331326
15. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-9; PMID:12915431; http://dx.doi.org/10.1001/jama.290.6.781
16. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-15; PMID: 15100338; http://dx.doi.org/10.1093/jnci/djh104
17. Rogoza RM, Ferko N, Bentley J, Meijer CJ, Berkhof J, Wang KL, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008; 26(Suppl 5): F46-58; PMID:18992382; http://dx.doi.org/ 10.1016/j.vaccine.2008.02.039
18. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100:308-20; PMID:18314477; http://dx.doi.org/10.1093/jnci/djn019
19. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37-48; PMID:12533280
20. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915-23; PMID:15550200
21. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28-41; PMID:17370513; http://dx.doi.org/10.3201/eid1301.060438
22. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14:244-51;PMID:18258117; http://dx.doi.org/10.3201/eid1402.070499
23. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32; PMID:18716299; http://dx.doi.org/10.1056/NEJMsa0707052
24. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884; PMID:19815582; http://dx.doi.org/10.1136/bmj.b3884
25. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151:538-45; PMID:19841455
26. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13:89-102; PMID:8483408; http://dx.doi.org/10. 1177/0272989X9301300202
27. Fryback DG, Lawrence WF, Jr. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 1997; 17:276-84; PMID:9219187; http://dx.doi.org/10.1177/0272989X9701700303
28. Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr 2009; 155:21-5, 25, e1-5; PMID: 19394030; http://dx.doi.org/10.1016/j.jpeds.2009.01.040
29. Federal Bureau of Statistics Germany Destatis. www.destatis.de, accessed on 22.10.2010.
30. Soergel P, Hillemanns P. [Treatment of cervical dysplasia with conisation in Germany]. Frauenarzt. 2011; 3:210-5.
31. Schwabe U, Paffrath D, eds. [Medication prescription report 2009. Actual data, costs, trends and comments]. Springer 2009, Berlin.
32. Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, et al. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess 2010; 6:Doc05; PMID:21289878
33. Hille ET, Weisglas-Kuperus N, van Goudoever JB, Jacobusse GW, Ens-Dokkum MH, de Groot L, et al &Dutch Collaborative POPS 19 Study Group. Functional outcomes and participation in young adulthood for very preterm and very low birth weight infants: the Dutch Project on Preterm and Small for Gestational Age Infants at 19 years of age. Pediatrics 2007; 120:e587-95; PMID:17766499; http://dx.doi.org/10.1542/peds.2006-2407
34. Larroque B, Ancel PY, Marret S, Marchand L, AndréM, Arnaud C, et al & EPIPAGE Study group. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet 2008; 371:813-20; PMID:18328928; http://dx.doi.org/10.1016/S0140-6736(08)60380-3
35. Wilson-Costello D. Is there evidence that long-term outcomes have improved with intensive care? Semin Fetal Neonatal Med 2007; 12:344-54; PMID:17698428; http://dx.doi.org/10.1016/j.siny.2007.06.010
36. Costeloe K & EPICure Study Group. EPICure: facts and figures: why preterm labour should be treated. BJOG 2006; 113(Suppl 3):10-2; PMID:17206960; http://dx.doi.org/10.1111/j.1471-0528.2006.01118.x
37. Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell V, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010; 182:237-45; PMID:20378729; http://dx.doi.org/10.1164/rccm.200912-1806OC
38. Johnson S, Hennessy E, Smith R, Trikic R, Wolke D, Marlow N. Academic attainment and special educational needs in extremely preterm children at 11 years of age: the EPICure study. Arch Dis Child Fetal Neonatal Ed 2009; 94:F283-9; PMID:19282336; http://dx.doi.org/10.1136/adc.2008.152793
39. Hack M, Flannery DJ, Schluchter M, Cartar L, Borawski E, Klein N. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002; 346:149-57; PMID:11796848; http://dx.doi.org/10.1056/NEJMoa010856
40. Hack M, Youngstrom EA, Cartar L, Schluchter M, Taylor HG, Flannery D, et al. Behavioral outcomes and evidence of psychopathology among very low birth weight infants at age 20 years. Pediatrics 2004; 114: 932-40; PMID:15466087; http://dx.doi.org/10.1542/peds.2003-1017-L
41. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med 2000; 343:378-84; PMID:10933736; http://dx.doi.org/10.1056/ NEJM200008103430601
42. MacKay DF, Smith GC, Dobbie R, Pell JP. Gestational age at delivery and special educational need: retrospective cohort study of 407,503 schoolchildren. PLoS Med 2010; 7:e1000289; PMID:20543995; http://dx.doi.org/10.1371/journal. pmed.1000289
43. Platt MJ, Cans C, Johnson A, Surman G, Topp M, Torrioli MG, et al. Trends in cerebral palsy among infants of very low birthweight (<1500 g) or born prematurely (<32 weeks) in 16 European centres: a database study. Lancet 2007; 369:43-50; PMID:17208641; http://dx.doi.org/10.1016/S0140-6736(07)60030-0
44. Saigal S, Rosenbaum P. What matters in the long term: reflections on the context of adult outcomes versus detailed measures in childhood. Semin Fetal Neonatal Med 2007; 12:415-22; PMID:17707702; http://dx.doi.org/10.1016/j.siny. 2007.06.006
45. Watts JL, Saigal S. Outcome of extreme prematurity: as information increases so do the dilemmas. Arch Dis Child Fetal Neonatal Ed 2006; 91:F221-5; PMID: 16632651; http://dx.doi.org/10.1136/adc.2005.071928
46. Hoehn T, Drabik A, Lehmann C, Christaras A, Stannigel H, Mayatepek E. Correlation between severity of disease and reimbursement of costs in neonatal and paediatric intensive care patients. Acta Paediatr 2008; 97:1438-42; PMID:18616633; http://dx.doi.org/10.1111/j.1651-2227.2008.00926.x
47. AQUA - Institute of applied Quality Promotion and Research in Health System GmbH. Federal evaluation of the year 2009, 16/1 - Obstetrics. www.aqua-institut. de, data on file. 2010.
48. Center for Quality Management in Health Care of the Medical Council of Lower Saxony. Obstetric evalutation of Lower Saxony 2009. http://www.zq-aekn.de/ , accessed 22.10.2010.
49. Association of University Clinics Germany e. V. Commentary of the Association of University Clinics Germany e.V on treatment of preterm infants in Germany. 2010; http://www.uniklinika.de/media/file/2766.2010-10-08-Kommentar- des-VUD-zur-Fruehgeborenenversorgung.pdf, accessed 22.10.2010.
50. Center for Quality Management in Health Care of the Medical Council of Lower Saxony. Neonatal evalutation of Lower Saxony 2009. www.zq-aekn.de, accessed 23.12.2010.